Popular Trials
Serine Protease Inhibitor
Anti-Inflammatory Therapy for Chronic Pancreatitis
This trial will study whether two anti-inflammatory therapies can reduce damage to transplanted islets and improve long-term outcomes for patients with severe chronic pancreatitis who have had their pancreas removed and their islets transplanted into the liver.
Procedure
Endoscopic Surgery Techniques for Pancreatitis
This trial compares two methods of using a camera and tools through the mouth to remove dead tissue from the pancreas in patients with necrotizing pancreatitis. One method does it all at once, while the other does it gradually. The goal is to see which method works better for these patients.
Non-Opioid Analgesic
Non-Opioid vs. Opioid Pain Management for Pediatric Pancreatitis
This trial will compare two methods of pain relief for kids with pancreatitis in the emergency room. One group will get the usual care, which often includes opioids, and the other group will get an opioid-sparing method. The trial will help researchers understand how well the new method works and how to design a bigger, better trial.
Procedure
Pancreatic Endotherapy for Chronic Pancreatitis
This trial is testing whether treating chronic pancreatitis with just endoscopic ultrasound (EUS) is more effective at reducing pain than adding endoscopic retrograde cholangiopancreatography (ERCP) with pancreatic endotherapy.
Popular Filters
Trials for Acute Pancreatitis Patients
Behavioral Intervention
Online Pain Management for Chronic Pancreatitis
This trial aims to help people with chronic pancreatitis who suffer from severe abdominal pain. The study will use an online program to teach self-management techniques to reduce pain and improve quality of life. The goal
Corticosteroid
Corticosteroids for Acute Pancreatitis
This trial is testing if giving hydrocortisone can help patients with severe acute pancreatitis by reducing inflammation. The goal is to see if this treatment can improve their health and reduce the time they need to stay in the hospital. Hydrocortisone seems to be effective in treating the early inflammation associated with severe acute pancreatitis.
Behavioural Intervention
Intermittent Fasting for Pancreatitis
This trial is testing intermittent fasting to help people with recurrent acute and chronic pancreatitis. The fasting process releases fatty acids that turn into ketones, providing energy and reducing inflammation and scarring in the pancreas.
Behavioral Intervention
Web-based CBT for Pancreatitis
This trial will test a new web-based program to help manage pain in children with chronic and acute recurring pancreatitis, with the goal of reducing pain, pain-related disability and improving quality of life.
Cohort 1 for Acute Pancreatitis
Acute pancreatitis is a frequently devastating pancreatic inflammatory process that results in extensive morbidity, mortality, and hospitalization costs. The incidence of acute pancreatitis has been increasing over the last decade with an overall mortality rate of 5%, although it may be as high as 30% in the most severe cases. It was the most common inpatient gastrointestinal diagnosis in 2009, totaling over 270,000 hospitalizations with estimated "inpatient costs" of over 2.5 billion dollars in the United States. However, despite the significant impact to both patients and the healthcare system, there is no proven pharmacologic therapy that improves important clinical outcomes in acute pancreatitis. The release of bicarbonate rich fluid into the pancreatic duct from the ductal cells is an important mechanism to protect against pancreatitis by two distinct mechanisms: 1. "Flushing" activated enzymes out of the pancreas and into the duodenum thereby preventing accumulation of activated enzymes within the pancreatic acinus 2. Directly alkalinizing the acinar cells, which limits intra-acinar cell damage by improving trafficking of inappropriately activated intra-acinar enzymes along the apical membrane. In addition to standard care, patients will be divided into 4 cohorts. Cohorts 1,2 and 3 will be treated with different doses of intravenous synthetic human secretin. Cohort X will not receive human secretin, but all datapoints and specimens will be collected. The patient cohorts will be entered into the study as follows: Cohort X; Cohort 1; Cohort 2; Cohort 3. 5 patients in each cohort will be evaluated at each center (for a total of n=10 at both centers for each cohort). Dosing will start within 24 hours of hospitalization with no further synthetic human secretin administration beyond Day 3. Patients will continue to be followed for 7 days or until discharge, whichever comes first. Any data recorded to that point would be included in an intent-to-treat analysis. The primary objective is to perform a Phase II Pilot Study to explore the efficacy of intravenous synthetic human secretin as a pharmacologic adjunct to modulate the severity of human acute (non-obstructive) pancreatitis.
Trials for Chronic Pancreatitis Patients
Behavioral Intervention
Online Pain Management for Chronic Pancreatitis
This trial aims to help people with chronic pancreatitis who suffer from severe abdominal pain. The study will use an online program to teach self-management techniques to reduce pain and improve quality of life. The goal
Behavioural Intervention
Intermittent Fasting for Pancreatitis
This trial is testing intermittent fasting to help people with recurrent acute and chronic pancreatitis. The fasting process releases fatty acids that turn into ketones, providing energy and reducing inflammation and scarring in the pancreas.
Behavioral Intervention
Web-based CBT for Pancreatitis
This trial will test a new web-based program to help manage pain in children with chronic and acute recurring pancreatitis, with the goal of reducing pain, pain-related disability and improving quality of life.
QST for Chronic Pancreatitis
This trial will use a new technique, quantitative sensory testing (QST), to map pain patterns in people with chronic pancreatitis (CP). QST has the potential to improve treatment for CP and may eventually be able to predict response to CP therapies.
Trials With No Placebo
Diagnostic Test
Diagnostic Imaging for Pancreatitis
This trial seeks to understand how MRI can be used to identify pancreatitis & predict long-term complications. It includes tests like endoscopy, blood tests, stool tests & MRI scans. Some participants will receive intravenous secretin.
Behavioural Intervention
Intermittent Fasting for Pancreatitis
This trial is testing intermittent fasting to help people with recurrent acute and chronic pancreatitis. The fasting process releases fatty acids that turn into ketones, providing energy and reducing inflammation and scarring in the pancreas.
Behavioral Intervention
Web-based CBT for Pancreatitis
This trial will test a new web-based program to help manage pain in children with chronic and acute recurring pancreatitis, with the goal of reducing pain, pain-related disability and improving quality of life.
Cohort 1 for Acute Pancreatitis
Acute pancreatitis is a frequently devastating pancreatic inflammatory process that results in extensive morbidity, mortality, and hospitalization costs. The incidence of acute pancreatitis has been increasing over the last decade with an overall mortality rate of 5%, although it may be as high as 30% in the most severe cases. It was the most common inpatient gastrointestinal diagnosis in 2009, totaling over 270,000 hospitalizations with estimated "inpatient costs" of over 2.5 billion dollars in the United States. However, despite the significant impact to both patients and the healthcare system, there is no proven pharmacologic therapy that improves important clinical outcomes in acute pancreatitis. The release of bicarbonate rich fluid into the pancreatic duct from the ductal cells is an important mechanism to protect against pancreatitis by two distinct mechanisms: 1. "Flushing" activated enzymes out of the pancreas and into the duodenum thereby preventing accumulation of activated enzymes within the pancreatic acinus 2. Directly alkalinizing the acinar cells, which limits intra-acinar cell damage by improving trafficking of inappropriately activated intra-acinar enzymes along the apical membrane. In addition to standard care, patients will be divided into 4 cohorts. Cohorts 1,2 and 3 will be treated with different doses of intravenous synthetic human secretin. Cohort X will not receive human secretin, but all datapoints and specimens will be collected. The patient cohorts will be entered into the study as follows: Cohort X; Cohort 1; Cohort 2; Cohort 3. 5 patients in each cohort will be evaluated at each center (for a total of n=10 at both centers for each cohort). Dosing will start within 24 hours of hospitalization with no further synthetic human secretin administration beyond Day 3. Patients will continue to be followed for 7 days or until discharge, whichever comes first. Any data recorded to that point would be included in an intent-to-treat analysis. The primary objective is to perform a Phase II Pilot Study to explore the efficacy of intravenous synthetic human secretin as a pharmacologic adjunct to modulate the severity of human acute (non-obstructive) pancreatitis.
QST for Chronic Pancreatitis
This trial will use a new technique, quantitative sensory testing (QST), to map pain patterns in people with chronic pancreatitis (CP). QST has the potential to improve treatment for CP and may eventually be able to predict response to CP therapies.
View More Related Trials
Frequently Asked Questions
Introduction to
What are the top hospitals conducting undefined research?
When it comes to cutting-edge clinical trials in an unspecified medical condition, several top hospitals are leading the way. In Pittsburgh, the University of Pittsburgh Medical Center is making significant strides with four active trials and a total of eight completed studies dedicated to this mysterious condition. Since their first recorded trial in 2010, they have been at the forefront of uncovering breakthroughs in diagnosis and treatment.
Meanwhile, the University of Minnesota in Minneapolis has also demonstrated its commitment to advancing knowledge about this enigmatic ailment. With three ongoing undefined trials and a history of eight previous investigations since initiating their first trial in 2010, they are actively contributing to our understanding of this condition.
Taking part in this important research is the Medical University of South carolina located in Charleston. They currently have three active undefined trials underway and have already conducted twelve such studies since recording their initial trial back in 2011. Their dedication speaks volumes about their determination to unravel the mysteries behind this complex illness.
In Cincinnati, researchers at The Cincinnati Children's Hospital Medical Center are tirelessly working towards finding answers as well. While having two ongoing undefined clinical trials, they have previously conducted six exploratory investigations since embarking on their pioneering journey just seven years ago during 2014.
Lastly joining these prestigious institutions' efforts is Beth Israel Deaconess Medical Center situated within Boston's medical hub. With two current undefined clinical trials underway and seven previous studies under their belt since recording their debut experiment back during 2004; theirs' too signifies an unwavering commitment toward tackling unknown aspects related to aforementioned health concern.
These notable hospitals epitomize how collaboration between esteemed institutions across different locations can bring us closer to solving medical mysteries that impact countless lives worldwide
Which are the best cities for undefined clinical trials?
When it comes to undefined clinical trials, several cities show promise in ongoing research and development. Los Angeles, California leads the way with 8 active trials exploring treatments like 0.5 mg/kg (0.3125 mL/kg), ERCP with miES, and Regular Diet interventions. Indianapolis, Indiana follows closely behind with 5 ongoing studies focused on advancements such as ERCP with miES and Dose Escalation Level assessments. Additionally, Pittsburgh, Pennsylvania and Charleston, South carolina both have 4 active trials investigating various approaches including ERCP with miES and Quantitative Sensory Test 1 evaluations. Baltimore, Maryland also joins these cities in offering potential breakthroughs through its own set of 4 active trials examining treatments like Rectal Indomethacin. These cities provide individuals participating in undefined clinical trials access to cutting-edge research that may contribute to improved patient outcomes in the future.
Which are the top treatments for undefined being explored in clinical trials?
Clinical trials are paving the way for innovative treatments in undefined conditions. Among the top contenders, ketorolac and rectal indomethacin are currently being explored in two active trials each, with five and three all-time undefined trials respectively. These treatments have been making strides since their introduction in 2016 and 2014 respectively. Additionally, proton pump inhibitors and hydrocortisone show promise with one active trial each, marking a new era of potential therapies that could offer hope to patients facing these undefined conditions as early as 2023 and 2022 respectively. The relentless pursuit of scientific discovery continues to push boundaries and bring us closer to effective treatment options.
What are the most recent clinical trials for undefined?
The field of clinical trials is continuously advancing, with recent studies exploring new avenues for undefined conditions. One noteworthy trial involves the use of pirfenidone as a potential treatment option. With both Phase 1 and Phase 2 trials currently underway since August 2023, researchers are eager to evaluate its efficacy in addressing this condition. Additionally, another trial focuses on dose escalation levels specifically tailored for patients with undefined concerns, aiming to determine the optimal dosage for effective treatment. Lastly, imaging stratification of stages of pancreatitis has emerged as an area of interest within the medical community through a Phase 4 study that commenced in January 2023. These ongoing investigations hold promise in expanding our understanding and improving outcomes for individuals facing undefined conditions.
What undefined clinical trials were recently completed?
Recently, two clinical trials addressing undefined medical conditions have reached completion, representing significant progress in understanding and treating these ailments. In October 2021, AbbVie concluded a trial investigating the potential of CREON. Similarly, Mayo Clinic wrapped up a study testing Indomethacin in July 2020. These achievements highlight the ongoing efforts of researchers towards uncovering effective treatment options for complex medical conditions that are not explicitly specified here.